SAN DIEGO, July 24, 2025 /PRNewswire/ -- In emergency care settings, every second counts. Early drug detection not only improves clinical decision-making, it can be the difference between life and death. But with the rise of counterfeit medications and drug combinations that are more potent and less predictable, emergency departments must adapt faster than ever.
QuidelOrtho Science Bytes Episode 49 "How Urgent Diagnostic Testing Can Help Prevent Drug Overdose Deaths," addresses the escalating complexities of substance use detection and care in emergency departments across the country. The episode features Vonda McAllister, Director of Global Product Management at QuidelOrtho, whose deep experience in diagnostics and toxicology provides critical perspective on the clinical and societal impacts of today's most dangerous drug trends.
Subscribe to QuidelOrtho Science Bytes
Episode Highlights:
Key Quotes:
Vonda McCallister, Director of Global Product Management, QuidelOrtho
"As overdose presentations become more complex, continuous monitoring, comprehensive toxicology screening and clinical vigilance are essential tools in the fight against this crisis."
About QuidelOrtho Science Bytes
Science Bytes is a monthly podcast that delivers diagnostic insights and innovation updates from QuidelOrtho, helping healthcare providers stay informed and prepared. Episode 49 is now available on all major podcast platforms.
For more information and to listen to the full episode, visit www.quidelortho.com/sciencebytes.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of innovative diagnostic testing solutions. From infectious diseases to cardiac biomarkers to women's health, QuidelOrtho transforms the power of diagnostics into a healthier future through science, innovation, and accessibility. Learn more at www.quidelortho.com.
Source: QuidelOrtho Corporation
Investor Contact: Juliet Cunningham Vice President, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$27.90 |
Daily Change: | 2.24 8.73 |
Daily Volume: | 1,511,346 |
Market Cap: | US$1.890B |
August 19, 2025 August 13, 2025 August 05, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load